Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 14/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 12/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | LMNA | P02545 | 9/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 7/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112161 | 0.81 | EGFR (1.00) | EGFRCSF1R | |
| SCHEMBL31031351 | 0.80 | CYP1A2 (0.61) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL4357581 | 0.79 | ALDH1A1 (0.69) | CYP1A2CYP3A4CLK4ALDH1A1LMNA | |
| SCHEMBL25844376 | 0.79 | CYP1A2 (0.59) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL6598291 | 0.79 | CYP1A2 (0.59) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL4692556 | 0.75 | MAP4K4 (0.66) | EGFR | |
| SCHEMBL29713890 | 0.75 | MAP4K4 (0.66) | EGFR | |
| SCHEMBL31031354 | 0.75 | CYP1A2 (0.55) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL2880252 | 0.75 | CYP1A2 (0.55) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL7679077 | 0.74 | EGFR (0.51) | EGFRCYP1A2CYP3A4CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-6602863-B1 | Irreversible inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885CYP1A2 2106/4885CYP3A4 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.